Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain.
Ribera JM, García O, Buendía-Ureña B, Terol MJ, Vicent A, Vall-Llovera F, Bergua J, García-Cadenas I, Esteve J, Ribera J, Acuña-Cruz E, Herrera P, Hernández-Rivas JM, Abrisqueta P, González-Campos J, Rodríguez C, Bastos-Oreiro M, Genescà E, Caminos N, Queipo de Llano MP, Cladera A, Sancho JM; Members of PETHEMA: Josep-Maria Riberaa, Olga Garcíaa, Ferran Vall-Lloverae, Juan Berguaf, Irene García-Cadenasg, Jordi Esteveh, Jordi Riberaa, Evelyn Acuña-Cruzi, Jesus-Maria Hernández-Rivas, José González-Camposm, Eulàlia Genescàa, Maria-Paz Queipo de Llanoq, Antònia Claderar Members of GELTAMO: Buenaventura Buendía-Ureñab, Maria-José Terolc, Ana Vicentd, Pilar Herreraj, Pau Abrisquetal, Carlos Rodríguezn, Mariana Bastos-Oreiroo, Nerea Caminosp, Juan-Manuel Sanchoa Groups. Ribera JM, et al. Among authors: vall llovera f. Leuk Lymphoma. 2022 Aug;63(8):1993-1996. doi: 10.1080/10428194.2022.2053531. Epub 2022 Mar 27. Leuk Lymphoma. 2022. PMID: 35343365 No abstract available.
Pharmacogenetic analysis in the treatment of Hodgkin lymphoma.
Altés A, Paré L, Esquirol A, Xicoy B, Rámila E, Vicente L, López R, Orriols J, Vall-llovera F, Sánchez-González B, del Río E, Sureda A, Páez D, Baiget M. Altés A, et al. Leuk Lymphoma. 2013 Aug;54(8):1706-12. doi: 10.3109/10428194.2012.752080. Epub 2013 Feb 1. Leuk Lymphoma. 2013. PMID: 23323945
Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).
Ribera JM, García O, Grande C, Esteve J, Oriol A, Bergua J, González-Campos J, Vall-Llovera F, Tormo M, Hernández-Rivas JM, García D, Brunet S, Alonso N, Barba P, Miralles P, Llorente A, Montesinos P, Moreno MJ, Hernández-Rivas JÁ, Bernal T. Ribera JM, et al. Cancer. 2013 May 1;119(9):1660-8. doi: 10.1002/cncr.27918. Epub 2013 Jan 29. Cancer. 2013. PMID: 23361927 Free article. Clinical Trial.
Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients.
Xicoy B, Ribera JM, Müller M, García O, Hoffmann C, Oriol A, Hentrich M, Grande C, Wasmuth JC, Esteve J, van Lunzen J, Del Potro E, Knechten H, Brunet S, Mayr C, Escoda L, Schommers P, Alonso N, Vall-Llovera F, Pérez M, Morgades M, González J, Fernández A, Thoden J, Gökbuget N, Hoelzer D, Fätkenheuer G, Wyen C; PETHEMA Group and German HIV Lymphoma Cohort. Xicoy B, et al. Leuk Lymphoma. 2014 Oct;55(10):2341-8. doi: 10.3109/10428194.2013.878933. Epub 2014 Feb 25. Leuk Lymphoma. 2014. PMID: 24397614
Bilateral phrenic nerve palsy induced by subcutaneous bortezomib in a patient with newly diagnosed multiple myeloma: first case reported.
López M, Martínez Lacasa X, Martí JM, Muntañola A, Fernández M, Huertas S, Saumell S, De Diego I, Bustamante G, Mesa A, Canet M, Julià M, Vall-Llovera F. López M, et al. Leuk Lymphoma. 2017 Feb;58(2):482-484. doi: 10.1080/10428194.2016.1195496. Epub 2016 Jun 27. Leuk Lymphoma. 2017. PMID: 27348085 No abstract available.
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, Bermúdez A, Moreno MJ, González-Campos J, Vives S, Gil C, Abella E, Guàrdia R, Martínez-Carballeira D, Martínez-Sánchez P, Amigo ML, Mercadal S, Serrano A, López-Martínez A, Vall-Llovera F, Sánchez-Sánchez MJ, Peñarrubia MJ, Calbacho M, Méndez JA, Bergua J, Cladera A, Tormo M, García-Belmonte D, Feliu E, Ciudad J, Orfao A; PETHEMA Group, Spanish Society of Hematology. Ribera JM, et al. Leuk Lymphoma. 2018 Jul;59(7):1634-1643. doi: 10.1080/10428194.2017.1397661. Epub 2017 Nov 22. Leuk Lymphoma. 2018. PMID: 29165013 Clinical Trial.
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Ribera JM, García O, Gil C, Mercadal S, García-Cadenas I, Montesinos P, Barba P, Vives S, González-Campos J, Tormo M, Esteve J, López A, Moreno MJ, Ribera J, Alonso N, Bermúdez A, Amigo ML, Genescà E, García D, Vall-Llovera F, Bergua JM, Guàrdia R, Monteserín MC, Bernal T, Calbacho M, Martínez MP, Feliu E; PETHEMA Group. Ribera JM, et al. Leuk Res. 2018 May;68:79-84. doi: 10.1016/j.leukres.2018.03.010. Epub 2018 Mar 19. Leuk Res. 2018. PMID: 29574396
Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine.
Cabezón M, Bargay J, Xicoy B, García O, Borrás J, Tormo M, Marcé S, Pedro C, Valcárcel D, Jiménez MJ, Guàrdia R, Palomo L, Brunet S, Vall-Llovera F, Garcia A, Feliu E, Zamora L; CETLAM Group. Cabezón M, et al. Oncotarget. 2018 Apr 10;9(27):19342-19355. doi: 10.18632/oncotarget.25046. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721207 Free PMC article.
38 results